Inclusion Criteria:

- Diagnosis, within the previous 12 months with Stage I-III, infiltrating ductal
adenocarcinoma of the breast who have undergone surgery and chemotherapy and are able
to begin study treatment within 5 days after the last dose of radiotherapy

- Estrogen and/or progesterone receptor-negative or positive

- Willing to eat consistent diet throughout the study, and avoid dietary sources of
mushrooms

- Willing to avoid taking any product containing Trametes versicolor, other immune
modulating medicinal mushrooms, or other herbal products believed to have immune
modulating effects, during radiotherapy and until completion of the subject's last
clinic visit on the study.

- Adequate organ function within 14 days of study enrollment including the following:

- Adequate bone marrow reserve: White blood cells (WBC) ≥ 2,000/mm³, Platelet
count ≥ 100,000/mm³, Hemoglobin ≥ 9 g/dL

- Hepatic: Bilirubin ≤ 20% times upper limit of normal (ULN), Alkaline phosphatase
≤ 20% times ULN, AST and ALT ≤ 20% times ULN

- Renal: Creatinine ≤ 20% times ULN

- Nutritional status: Albumin ≥ 3.0 g/dL

- Negative pregnancy test

- Voluntary written consent before performance of any study-related procedure not part
of the normal medical care

Exclusion Criteria:

- Pregnant - Patients with reproductive potential must use an approved non-hormonal
contraceptive method if appropriate during and for 4 weeks after the last dose of
Trametes versicolor.

- Known allergy to fungi, including mushrooms

- Serious concurrent medical or psychiatric disorder (e.g., active infection or
uncontrolled diabetes) that, in the opinion of the investigator, would compromise the
safety of the patient or the patient's ability to complete the study

- Receipt of hematopoietic growth factors (e.g., Neupogen™, Epogen™) within the
previous 4 weeks

- Unwilling to maintain consistency in type and dose of concurrent complementary and
alternative medicine therapies

- Unwilling to discontinue excluded medications and supplements